Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
about
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerPotential role for metformin in urologic oncologyThe Crossroads of Geriatric Cardiology and Cardio-OncologyCardiovascular effects of hormone therapy for prostate cancerAdverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complicationsInfluence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapyImpact of Diet-Induced Obesity and Testosterone Deficiency on the Cardiovascular System: A Novel Rodent Model Representative of Males with Testosterone-Deficient Metabolic Syndrome (TDMetS)Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic reviewA phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.Clinical significance of androgen secretion disorders in men with a malignancy.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Prostate cancer: How can we improve the health of men who receive ADT?Cardiac and cognitive effects of androgen deprivation therapy: are they real?Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review.Contemporary role of androgen deprivation therapy for prostate cancerAn update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatmentAndrogen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyDevelopment and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) databaseTestosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).Cardiovascular risk during hormonal treatment in patients with prostate cancer.Metabolic effects of androgen deprivation therapyDiabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.Androgen deprivation therapy and cardiovascular risk.Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.Androgen-deprivation therapy and risk for biliary disease in men with prostate cancerAndrogen deprivation therapy is associated with diabetes: Evidence from meta-analysisProstate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an updateValidity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.An update on androgen deprivation therapy for prostate cancer.
P2860
Q26739708-506ED68E-ED83-4B28-B120-5EF8FE90B5D5Q26747759-BF160393-6F66-4950-9123-A37320983F58Q26778666-218084A6-002F-4019-B5D4-F787F7A6E4BAQ26801112-91D59801-0B66-40F5-874A-31027DFE3182Q26852930-CBA2D8FB-5610-409B-BF5D-D5538BD47E57Q27308917-AFCD7C6B-885A-4CCD-AA1C-5F0659D0D1F4Q27318055-F30D3D2A-C34E-4292-A872-408FCFC11C75Q28069320-05EF460F-A3CD-4E76-BB45-F3F838B24C38Q33443421-5B8A9EA0-58E4-4597-BC28-A15FE1C3D9E4Q33581390-46CBBFB9-79D4-4462-B360-44BDE2E1BEB3Q33754036-8DAB8C5E-5792-447D-940A-18F2C0839BA2Q33763924-6D911110-5090-496B-B360-0C887013A5E4Q33840617-90D6B44D-30AF-4732-ACF8-B31F0E2C55B8Q33977523-25E21D17-A48B-4F3F-BDE2-FAC62FC1832EQ33978336-9BB82886-0986-4736-9BA3-39CCD4CCE2C2Q34111628-99C77FE3-DAC5-446A-8E1F-4B8813200698Q34171941-E11AAF37-F187-45F1-B6D0-6B902A7BE55AQ34211155-73874B04-E135-47E0-B558-F0296F73B4F2Q34214898-7EFE899B-66FF-4AF8-85BA-3D0ED63CB305Q34267991-E8D43CBE-1E50-4826-9B75-706F4D57244EQ34411758-9EB344BC-5DC4-416C-B016-D325B1E43F71Q34505196-3A4AB896-D9C6-41AF-8B9E-2E4D5EACDAC6Q34615270-FD9C694B-F8D8-4544-8753-421E7A2A4AA1Q34663266-74A53A52-DAA4-4932-93A0-C4BEBC0B9B34Q34718357-3E9F1116-79E5-4B8E-AF77-CFDE6976C4FDQ34721165-C28D2478-1342-441F-BA53-3AE9152F827FQ34962416-DFA81DB1-843B-4F87-970B-EB1FB027C4A4Q35022837-43D12A8F-F952-4273-B781-C6F5C5688813Q35145672-BA405A91-91FB-4C9B-84BF-9DBA83255103Q35202889-1F1295E1-41D8-4E0E-9F34-ED7DD6D7C488Q35229730-BC73DE5B-B870-46A4-90CD-FCB297895249Q35689824-4D4A41E1-A652-47A1-8414-920D83A3B822Q35754723-7392678E-82D9-4D04-82EA-7D12EA76E463Q35756538-1A3C81CB-10A2-4F5B-9AEC-37B28B2A73F6Q35951635-A595449F-F869-4C4E-8A5D-A3A4E65E5643Q36018326-AD723C38-726C-4A4F-B751-D2E9B7CB3EAAQ36076214-F7B9A9D7-00AE-4420-B71F-FE9C15AD50E6Q36184923-7D0CC983-7CAB-43BD-B7D8-7B61CAA4637AQ36187103-38DD1D95-8ECA-455C-AD7B-FF58C691FE66Q36289952-DA60CBA8-6A9D-41B7-B100-2E8607922F94
P2860
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
@en
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
@nl
type
label
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
@en
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
@nl
prefLabel
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
@en
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
@nl
P2093
P2860
P356
P1476
Impact of androgen deprivation therapy on cardiovascular disease and diabetes
@en
P2093
Lawrence F Paszat
Minh Duong-Hua
Neil E Fleshner
Rinku Sutradhar
Shabbir M H Alibhai
P2860
P304
P356
10.1200/JCO.2008.20.0923
P407
P577
2009-06-08T00:00:00Z